ANIX
Anixa Biosciences Inc
Next earnings Sep 8, 2026 · consensus $-0.09 EPS
$2.79
▲ +6.49%$2.79▼ -20.06%
over 1Y
L $2.35EODHDH $5.22
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+6.5%
1W+0.7%
1M+5.3%
3M+9.4%
YTD-11.7%
1Y-20.1%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 9 analysts
Buy
Conservative balance sheet (liabilities/equity 0.14x); but unprofitable (net margin -5203.3%).
Revenue (FY2024) $210K · FY2024
Anixa Biosciences Inc shows $210K in FY2024 revenue (+0.0% YoY), a -5203.3% net margin, and -72.1% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $512K | — | $210K | $210K | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$13.1M | -$13.9M | -$11.0M | -$13.8M | -$11.7M |
| Net income | -$13.0M | -$13.6M | -$9.81M | -$12.6M | -$10.9M |
| Diluted EPS | — | $0.45 | -$0.32 | -$0.39 | -$0.34 |
| Net margin | -2530.1% | — | -4671.9% | -5978.1% | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$92.2M
EV / EBITDA—
EV / Sales439.3
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-11.7%
FCF yield-7.7%
Quality & risk
ROIC (est.)-59.5%
Free cash flow-$7.19M
Total debt$370K
Net cash$874K
Altman Z-Score2.97 grey
Piotroski F-Score2/7
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+3.7%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-162026-06-17open ↗4Period ending 2026-06-122026-06-16open ↗10-QPeriod ending 2026-04-302026-06-10open ↗8-KPeriod ending 2026-03-102026-03-11open ↗10-QPeriod ending 2026-01-312026-03-09open ↗8-KPeriod ending 2026-02-092026-02-09open ↗4Period ending 2026-01-282026-01-29open ↗DEF 14APeriod ending 2026-01-282026-01-28open ↗S-8Filing2026-01-12open ↗10-KPeriod ending 2025-10-312026-01-12open ↗SCHEDULE 13D/AFiling2026-01-06open ↗4Period ending 2026-01-052026-01-06open ↗
Frequently asked
- Is Anixa Biosciences Inc (ANIX) a buy?
- ANIX currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.14x); but unprofitable (net margin -5203.3%).
- What is Anixa Biosciences Inc's quality score?
- ANIX scores 42.29411764705882/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000715446, latest 10-Q filed 2026-06-10) · EODHD · as of 6/26/2026, 7:04:02 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.